About the program
Impact Scaling is a Thematic Tech Transfer (TTT) program established to bridge the gap between scientific research and commercial application. The program focuses on promising academic innovations in the field of chronic diseases, with the aim of bringing these innovations from the lab to the patient more quickly and effectively.

Available TTT support
Within the program, the transition from groundbreaking research to an investable business case is supported through both advisory services and targeted funding for activities that often fall outside the scope of traditional research grants. These include activities required to move toward an investable case, such as:

• IP/strategy & freedom-to-operate (FTO) advice, market and user validation
• Regulatory/clinical pathways, reimbursement and implementation exploration
• Prototype/feasibility steps and positioning of the value proposition

This valorization voucher covers costs incurred by third parties up to a maximum of €25,000 (incl. VAT).

End goal
The aim is to support researchers on their path toward valorization, the development of an investable case, and the establishment of a startup, so that scientific breakthroughs can more rapidly grow into concrete solutions for patients and improve healthcare.

Collaboration
Over the past five years, the Dutch Cardiovascular Alliance (DCVA) and RegMed XB have worked together on the successful program Impact Acceleration, in collaboration with BioGeneration Ventures (BGV) as the experienced fund manager of the FIRST pre-seed fund, an essential instrument for financing new academic startups.

Proven approach
In the first TTT program (2020–2025), 42 voucher projects and 14 startups were supported; participating companies jointly raised over €62 million in follow-on funding. Visit the website for more information and real-world stories from entrepreneurial teams supported by RegMed XB and DCVA:
https://regmedxb.com/what/business-development-valorization

Or contact one of the Impact Officers directly for a no-obligation advisory meeting:

• Nick Beijer: Impact Officer RegMed XB, n.beijer@regmedxb.com
• Luc Schoppink: Impact Officer DCVA, l.schoppink@dcvalliance.nl